Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. [electronic resource]
Producer: 20120119Description: 1352-4 p. digitalISSN:- 1097-6825
- Antirheumatic Agents -- therapeutic use
- Autoimmune Diseases -- drug therapy
- Female
- Hereditary Autoinflammatory Diseases -- drug therapy
- Humans
- Interleukin 1 Receptor Antagonist Protein -- therapeutic use
- Interleukin-1 -- antagonists & inhibitors
- Interleukin-1beta -- metabolism
- Schnitzler Syndrome -- drug therapy
- Tumor Necrosis Factor-alpha -- metabolism
No physical items for this record
Publication Type: Letter; Research Support, Non-U.S. Gov't; Comment
There are no comments on this title.
Log in to your account to post a comment.